Literature DB >> 24026710

Atrial fibrillation ablation in octogenarians: where do we stand?

Gevorg Stepanyan1, Edward P Gerstenfeld.   

Abstract

The prevalence of atrial fibrillation increases significantly with age, affecting nearly 10 % of adults greater than 80 years of age. Complications from atrial fibrillation, including stroke, also increase with age. Medical therapy includes anticoagulation, ventricular rate control, and if symptoms persist, maintenance of sinus rhythm with antiarrhythmic drugs. However, anticoagulation and antiarrhythmic therapy is often challenging in the elderly due to side effects, comorbidities, and heightened sensitivity to medications. Catheter based ablation of atrial fibrillation is an effective treatment for paroxysmal atrial fibrillation. However, the major randomized controlled trials, such as Thermocool AF and STOP-AF studies, have excluded the elderly patients. Current guidelines suggest caution when considering ablation for elderly patients due to a lack of available data. We will review recent studies that have observed the outcomes of atrial fibrillation ablation in the elderly, specifically those studies that included octogenarians.

Entities:  

Mesh:

Year:  2013        PMID: 24026710     DOI: 10.1007/s11886-013-0406-y

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN: 1523-3782            Impact factor:   2.931


  17 in total

1.  2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (Updating the 2006 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

Authors:  L Samuel Wann; Anne B Curtis; Craig T January; Kenneth A Ellenbogen; James E Lowe; N A Mark Estes; Richard L Page; Michael D Ezekowitz; David J Slotwiner; Warren M Jackman; William G Stevenson; Cynthia M Tracy; Valentin Fuster; Lars E Rydén; David S Cannom; Jean-Yves Le Heuzey; Harry J Crijns; James E Lowe; Anne B Curtis; S Bertil Olsson; Kenneth A Ellenbogen; Eric N Prystowsky; Jonathan L Halperin; Juan Luis Tamargo; G Neal Kay; L Samuel Wann; Alice K Jacobs; Jeffrey L Anderson; Nancy Albert; Judith S Hochman; Christopher E Buller; Frederick G Kushner; Mark A Creager; Erik Magnus Ohman; Steven M Ettinger; William G Stevenson; Robert A Guyton; Lynn G Tarkington; Jonathan L Halperin; Clyde W Yancy
Journal:  J Am Coll Cardiol       Date:  2010-12-21       Impact factor: 24.094

Review 2.  Amiodarone for atrial fibrillation.

Authors:  Peter Zimetbaum
Journal:  N Engl J Med       Date:  2007-03-01       Impact factor: 91.245

3.  Long-term clinical efficacy and risk of catheter ablation for atrial fibrillation in octogenarians.

Authors:  T Jared Bunch; J Peter Weiss; Brian G Crandall; Heidi T May; Tami L Bair; Jeffrey S Osborn; Jeffrey L Anderson; Donald L Lappe; J Brent Muhlestein; Jennifer Nelson; John D Day
Journal:  Pacing Clin Electrophysiol       Date:  2009-11-02       Impact factor: 1.976

4.  The cardiac arrhythmia suppression trial (CAST).

Authors:  J N Ruskin
Journal:  N Engl J Med       Date:  1989-08-10       Impact factor: 91.245

Review 5.  Age as a risk factor for stroke in atrial fibrillation patients: implications for thromboprophylaxis.

Authors:  Ricarda Marinigh; Gregory Y H Lip; Nicola Fiotti; Carlo Giansante; Deirdre A Lane
Journal:  J Am Coll Cardiol       Date:  2010-09-07       Impact factor: 24.094

6.  Catheter ablation of atrial fibrillation in octogenarians: safety and outcomes.

Authors:  Pasquale Santangeli; Luigi Di Biase; Prasant Mohanty; J David Burkhardt; Rodney Horton; Rong Bai; Sanghamitra Mohanty; Agnes Pump; Douglas Gibson; Linda Couts; Richard Hongo; Salwa Beheiry; Andrea Natale
Journal:  J Cardiovasc Electrophysiol       Date:  2012-04-11

7.  Frequency of symptomatic atrial fibrillation in patients enrolled in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study.

Authors:  Andrew E Epstein; Humberto Vidaillet; H Leon Greene; Anne B Curtis; Kenneth A Ellenbogen; Todd Simmons; Mary Mickel
Journal:  J Cardiovasc Electrophysiol       Date:  2002-07

8.  Cryoballoon ablation of pulmonary veins for paroxysmal atrial fibrillation: first results of the North American Arctic Front (STOP AF) pivotal trial.

Authors:  Douglas L Packer; Robert C Kowal; Kevin R Wheelan; James M Irwin; Jean Champagne; Peter G Guerra; Marc Dubuc; Vivek Reddy; Linda Nelson; Richard G Holcomb; John W Lehmann; Jeremy N Ruskin
Journal:  J Am Coll Cardiol       Date:  2013-03-21       Impact factor: 24.094

9.  Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: a randomized controlled trial.

Authors:  David J Wilber; Carlo Pappone; Petr Neuzil; Angelo De Paola; Frank Marchlinski; Andrea Natale; Laurent Macle; Emile G Daoud; Hugh Calkins; Burr Hall; Vivek Reddy; Giuseppe Augello; Matthew R Reynolds; Chandan Vinekar; Christine Y Liu; Scott M Berry; Donald A Berry
Journal:  JAMA       Date:  2010-01-27       Impact factor: 56.272

10.  Comparison of Atrial Fibrillation in the Young versus That in the Elderly: A Review.

Authors:  Rajiv Sankaranarayanan; Graeme Kirkwood; Katharine Dibb; Clifford J Garratt
Journal:  Cardiol Res Pract       Date:  2013-01-22       Impact factor: 1.866

View more
  2 in total

1.  Recurrent acute myocardial infarction and atrial fibrillation.

Authors:  Levent Cerit
Journal:  J Geriatr Cardiol       Date:  2017-02       Impact factor: 3.327

2.  Comparison of long-term outcome between patients aged < 65 years vs. ≥ 65 years after atrial fibrillation ablation.

Authors:  Zsuzsanna Kis; Anna Me Noten; Mihran Martirosyan; Astrid A Hendriks; Rohit Bhagwandien; Tamas Szili-Torok
Journal:  J Geriatr Cardiol       Date:  2017-09       Impact factor: 3.327

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.